Cerity Partners LLC Purchases 5,043 Shares of Immunome, Inc. (NASDAQ:IMNM)

Cerity Partners LLC raised its holdings in shares of Immunome, Inc. (NASDAQ:IMNM) by 10.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 53,103 shares of the company’s stock after acquiring an additional 5,043 shares during the period. Cerity Partners LLC’s holdings in Immunome were worth $776,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Sofinnova Investments Inc. raised its position in Immunome by 10.3% in the 2nd quarter. Sofinnova Investments Inc. now owns 655,680 shares of the company’s stock worth $7,934,000 after purchasing an additional 61,284 shares during the period. Victory Capital Management Inc. grew its stake in shares of Immunome by 48.1% during the third quarter. Victory Capital Management Inc. now owns 730,785 shares of the company’s stock valued at $10,684,000 after buying an additional 237,497 shares during the last quarter. Cetera Investment Advisers purchased a new position in shares of Immunome in the first quarter worth about $3,038,000. Ensign Peak Advisors Inc bought a new stake in shares of Immunome in the 2nd quarter valued at about $1,379,000. Finally, Rhumbline Advisers purchased a new stake in Immunome during the 2nd quarter valued at about $813,000. 44.58% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Immunome

In other news, insider Robert Lechleider acquired 15,805 shares of the stock in a transaction on Thursday, November 21st. The stock was acquired at an average price of $9.48 per share, with a total value of $149,831.40. Following the completion of the transaction, the insider now owns 15,805 shares of the company’s stock, valued at $149,831.40. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Clay B. Siegall bought 66,057 shares of the company’s stock in a transaction dated Thursday, November 21st. The shares were acquired at an average price of $9.54 per share, for a total transaction of $630,183.78. Following the acquisition, the chief executive officer now owns 485,693 shares in the company, valued at approximately $4,633,511.22. This represents a 15.74 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 102,862 shares of company stock valued at $978,045. 8.60% of the stock is currently owned by company insiders.

Immunome Stock Down 6.2 %

Shares of Immunome stock opened at $12.70 on Friday. The business has a 50 day moving average of $12.27 and a 200 day moving average of $13.48. Immunome, Inc. has a 52 week low of $6.93 and a 52 week high of $30.96. The company has a market cap of $792.70 million, a PE ratio of -1.57 and a beta of 1.83.

Analysts Set New Price Targets

IMNM has been the topic of a number of analyst reports. Wedbush reaffirmed an “outperform” rating and issued a $33.00 price target on shares of Immunome in a research note on Friday, October 25th. Stephens began coverage on shares of Immunome in a research note on Friday, November 8th. They issued an “overweight” rating and a $30.00 target price on the stock. Finally, Piper Sandler dropped their price target on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a research report on Thursday, November 14th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $28.83.

Immunome Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.